Psychemedics

Psychemedics Corporation provides testing services for the detection of drugs of abuse through the analysis of hair samples in the United States, Brazil, and internationally. The company offers screening and confirmation by mass spectrometry using industry-accepted practices for cocaine, marijuana, and PCP; amphetamines, including ecstasy, eve, and Adderall; opiates, such as heroin, hydrocodone, hydromorphone, oxycodone, oxymorphone, and codeine; synthetic cannabinoids comprising K2, Spice, and Blaze; benzodiazepines consisting of Xanax, Valium, and Ativan; and nicotine and Fentanyl. Its testing results provide quantitative information that could indicate the approximate amount of drug ingested, as well as historical data that could show a pattern of individual drug use over a longer period-of-time. The company offers its services to employers for applicant and employee testing; and treatment professionals, law enforcement agencies, school administrators, and parents concerned about their children's drug use. Psychemedics Corporation was incorporated in 1986 and is headquartered in Acton, Massachusetts.

Our mission is to provide companies with an efficient, reliable and accurate method to test their employees for the presence of substance abuse.

Our vision is to be the premier provider of services to help businesses around the world reduce the cost and risks associated with drug use in the workplace.

Psychemedics Corporation has won numerous awards for its innovative technology. In 2000 it was the first company to receive the 'Technology of the Year' Award from the American Drug Testing Industry Association, and in 2001 it received the 'Most Innovative Technology' award from the International Association of Drug Testing Laboratories.